Cargando…

Serglycin: At the Crossroad of Inflammation and Malignancy

Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Korpetinou, Angeliki, Skandalis, Spyros S., Labropoulou, Vassiliki T., Smirlaki, Gianna, Noulas, Argyrios, Karamanos, Nikos K., Theocharis, Achilleas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888995/
https://www.ncbi.nlm.nih.gov/pubmed/24455486
http://dx.doi.org/10.3389/fonc.2013.00327
_version_ 1782299139933995008
author Korpetinou, Angeliki
Skandalis, Spyros S.
Labropoulou, Vassiliki T.
Smirlaki, Gianna
Noulas, Argyrios
Karamanos, Nikos K.
Theocharis, Achilleas D.
author_facet Korpetinou, Angeliki
Skandalis, Spyros S.
Labropoulou, Vassiliki T.
Smirlaki, Gianna
Noulas, Argyrios
Karamanos, Nikos K.
Theocharis, Achilleas D.
author_sort Korpetinou, Angeliki
collection PubMed
description Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the granules and their protection since they are secreted as complexes and delivered to their targets after secretion. During the last decade, numerous studies have demonstrated that serglycin is also synthesized by various non-hematopoietic cell types. It has been shown that serglycin is highly expressed by tumor cells and promotes their aggressive phenotype and confers resistance against drugs and complement system attack. Apart from its direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the tumor cell microenvironment thus enhancing tumor development. In the present review, we discuss the role of serglycin in inflammation and tumor progression.
format Online
Article
Text
id pubmed-3888995
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38889952014-01-22 Serglycin: At the Crossroad of Inflammation and Malignancy Korpetinou, Angeliki Skandalis, Spyros S. Labropoulou, Vassiliki T. Smirlaki, Gianna Noulas, Argyrios Karamanos, Nikos K. Theocharis, Achilleas D. Front Oncol Oncology Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the granules and their protection since they are secreted as complexes and delivered to their targets after secretion. During the last decade, numerous studies have demonstrated that serglycin is also synthesized by various non-hematopoietic cell types. It has been shown that serglycin is highly expressed by tumor cells and promotes their aggressive phenotype and confers resistance against drugs and complement system attack. Apart from its direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the tumor cell microenvironment thus enhancing tumor development. In the present review, we discuss the role of serglycin in inflammation and tumor progression. Frontiers Media S.A. 2014-01-13 /pmc/articles/PMC3888995/ /pubmed/24455486 http://dx.doi.org/10.3389/fonc.2013.00327 Text en Copyright © 2014 Korpetinou, Skandalis, Labropoulou, Smirlaki, Noulas, Karamanos and Theocharis. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Korpetinou, Angeliki
Skandalis, Spyros S.
Labropoulou, Vassiliki T.
Smirlaki, Gianna
Noulas, Argyrios
Karamanos, Nikos K.
Theocharis, Achilleas D.
Serglycin: At the Crossroad of Inflammation and Malignancy
title Serglycin: At the Crossroad of Inflammation and Malignancy
title_full Serglycin: At the Crossroad of Inflammation and Malignancy
title_fullStr Serglycin: At the Crossroad of Inflammation and Malignancy
title_full_unstemmed Serglycin: At the Crossroad of Inflammation and Malignancy
title_short Serglycin: At the Crossroad of Inflammation and Malignancy
title_sort serglycin: at the crossroad of inflammation and malignancy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888995/
https://www.ncbi.nlm.nih.gov/pubmed/24455486
http://dx.doi.org/10.3389/fonc.2013.00327
work_keys_str_mv AT korpetinouangeliki serglycinatthecrossroadofinflammationandmalignancy
AT skandalisspyross serglycinatthecrossroadofinflammationandmalignancy
AT labropoulouvassilikit serglycinatthecrossroadofinflammationandmalignancy
AT smirlakigianna serglycinatthecrossroadofinflammationandmalignancy
AT noulasargyrios serglycinatthecrossroadofinflammationandmalignancy
AT karamanosnikosk serglycinatthecrossroadofinflammationandmalignancy
AT theocharisachilleasd serglycinatthecrossroadofinflammationandmalignancy